Moderna Plans $2B Zero-Coupon Convertible, Capped Call Limits Dilution

Moderna Inc. plans to raise $2 billion through a zero-coupon convertible senior note offering due 2031, the company said in a filing Monday. The notes are convertible into cash, shares of common stock, or a combination of both, at Moderna's election.

The biotech also entered capped call transactions with counterparties, a structure designed to reduce potential dilution from conversion. The capped calls effectively raise the conversion premium above the base terms, meaning fewer new shares would be issued if the stock trades above the conversion price at maturity.

Moderna said it intends to use the proceeds for general corporate purposes, which may include capital expenditures, working capital, and potential acquisitions or strategic investments. The company ended the first quarter with roughly $8.5 billion in cash and investments.

The zero-coupon structure means the notes will not pay periodic interest, but will accrete to par by maturity. Investors receive the full principal at maturity if not converted, with the return coming entirely from the discount at issuance.

Convertible debt has been a recurring financing tool for Moderna. The company issued $1.3 billion in convertible notes in 2021 and another $1 billion in 2023. The latest offering is the largest convertible deal Moderna has marketed.

The capped call transactions are standard for large convertible issuances. They involve counterparties, typically large banks, that hedge the equity exposure, allowing the issuer to reduce or eliminate the dilution that would otherwise occur when bondholders convert. The cost of the capped calls reduces the net proceeds from the offering.

Moderna shares have fallen about 35% this year through Monday's close, pressured by declining Covid-19 vaccine sales and uncertainty around its respiratory syncytial virus (RSV) vaccine timeline. The company's only marketed product remains its Covid shot, though it has a pipeline of mRNA-based candidates in oncology, rare disease, and infectious disease.

The company's Alpha Score of 58 places it in the Moderate category, reflecting a balanced risk-reward profile given the pipeline potential offset by the lack of near-term commercial diversification.

Zero-coupon convertibles appeal to issuers wanting to avoid near-term cash interest expense, particularly when stock volatility is high enough to make the conversion option valuable to buyers. Moderna's stock has a 60-day implied volatility above 70%, making the equity-linked feature attractive to hedge fund and arbitrage investors who typically anchor such deals.

The offering is expected to close later this week, subject to customary conditions. The conversion premium and coupon terms will be set at pricing, expected Tuesday or Wednesday.

For existing shareholders, the key variable is the capped call strike. If the capped call is set well above the conversion price, dilution from conversion is contained. If the stock surges past both levels, the counterparty hedging can create downward pressure on the shares as the banks sell stock to hedge their exposure.

Moderna's balance sheet remains strong by biotech standards. The $2 billion raise adds to a cash pile that gives the company flexibility to fund its pipeline through multiple late-stage readouts without needing near-term revenue growth from new products. But the convertible structure also signals that management sees the current stock price as an attractive entry point for equity-linked financing, a view that may not comfort investors already nursing year-to-date losses.